# Ibrutinib (PCI-32765) in Waldenstrom's Macroglobulinemia

> **NCT01614821** · PHASE2 · COMPLETED · sponsor: **Dana-Farber Cancer Institute** · enrollment: 63 (actual)

## Conditions studied

- Waldenstrom's Macroglobulinemia

## Interventions

- **DRUG:** PCI-32765

## Key facts

- **NCT ID:** NCT01614821
- **Lead sponsor:** Dana-Farber Cancer Institute
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2012-05
- **Primary completion:** 2016-09-09
- **Final completion:** 2018-09-15
- **Target enrollment:** 63 (ACTUAL)
- **Last updated:** 2020-01-21


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01614821

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01614821, "Ibrutinib (PCI-32765) in Waldenstrom's Macroglobulinemia". Retrieved via AI Analytics 2026-07-01 from https://api.ai-analytics.org/clinical/NCT01614821. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*